Immunic, Inc. · NASDAQ:IMUX

Immunic — Technical Presentation (September 2022)

29 slides from Immunic's technical presentation, Sep 20, 2022

  1. Slide 1: IMU-856: Phase 1 SAD/MAD Data in Healthy Human Subjects

    Immunic Therapeutics IMU-856: Phase 1 SAD/MAD Data in Healthy Human Subjects NASDAQ: IMUX | September 20, 2022

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities

  3. Slide 3: Advanced Clinical Pipeline

    Advanced Clinical Pipeline Three Differentiated Programs in Various Phases of Clinical Development Program Target Preclinical Phase 1 Phase 2 Phase 3 Key Milestones § RMS interim analysis planned after approx. Relapsing Multiple Sclerosis (RMS) – ENSURE Trials half of the events occurred Vidofludimu

  4. Slide 4: IMU-856: Phase 1 SAD/MAD Data in Healthy Human Subjects

    IMU-856: Phase 1 SAD/MAD Data in Healthy Human Subjects 01 Phase 1 Clinical Trial of IMU-856 § Trial Design and Study Population § Results Part A: Single Ascending Doses § Results Part B: Multiple Ascending Doses § Ongoing Part C in Patients with Celiac Disease 02 Q&A Session 03 Summary and Outlook

  5. Slide 5: Phase 1 Clinical Trial of IMU-856

    01 Phase 1 Clinical Trial of IMU-856 Results Part A: Results Part B: Trial Design Single Multiple and Status Ascending Doses Ascending Doses Ongoing Part C in Patients with Celiac Disease

  6. Slide 6: Phase 1 Clinical Trial: Trial Design and Current Status

    Phase 1 Clinical Trial: Trial Design and Current Status PART A PART B PART C Evaluation of Evaluation of Evaluation of single ascending doses (SAD) multiple ascending doses (MAD) patients with celiac disease receiving 28-day Healthy human subjects Healthy human subjects treatment of randomized to re

  7. Slide 7: Dose Escalation Algorithm

    Dose Escalation Algorithm Part A, Cohorts 1-6: Single Ascending Doses Cohort 6 160 mg IMU-856 or placebo (ratio 6:2) § Single oral tablet administration was performed. Cohort 5 120 mg IMU-856 or placebo (ratio 6:2) § Dosing in each cohort started with two sentinel participants: Cohort 4 80 mg IMU-85

  8. Slide 8: Dose-Linear Pharmacokinetics in Single Oral Dosing

    Dose-Linear Pharmacokinetics in Single Oral Dosing Part A, Cohorts 1-6 Median § Rapid absorption after oral tablet administration with peak (range) Mean (%CV) plasma concentration reached within 2 to 4 hours Tmax Cmax T1/2 AUCinf (hr) (ng/mL) (hr) (hr*ng/mL § Terminal plasma half-life of 16 to 20 ho

  9. Slide 9: Single Doses of IMU-856 Found to Have a Favorable Safety and Tolerability Profile

    Single Doses of IMU-856 in Healthy Human Subjects Found to Have a Favorable Safety and Tolerability Profile Part A, Cohorts 1-6 No serious adverse events No dose-dependency in adverse events No maximum tolerated dose reached No trends for post-dose changes in any laboratory parameter No related adve

  10. Slide 10: Conclusions

    Conclusions Part A: Single Ascending Doses § Single ascending oral doses of IMU-856 provided favorable pharmaceutical properties in Part A of this phase 1 clinical trial. § The favorable safety and tolerability profile allowed a smooth transition from Part A (SAD) to Part B (MAD) in healthy human su

  11. Slide 11: Dose Escalation Algorithm

    Dose Escalation Algorithm Part B, Cohorts 7, 7N-9N: Multiple Ascending Doses § Single daily oral tablet administration was performed over 14 Cohort 9N days. 160 mg IMU-856 or placebo (ratio 6:2) Cohort 8N § Dosing in each cohort started with two sentinel participants: 80 mg IMU-856 one randomized to

  12. Slide 12: Dose-Linear Pharmacokinetics in Multiple Dosing (Day 1 and 14)

    Dose-Linear Pharmacokinetics in Multiple Dosing (Day 1 and 14) Part B, Cohort 7N-9N § Terminal plasma half-life at steady state (Day 14 values) 17 to 21 hours comparable to single dose § Linear pharmacokinetics also after multiple dosing with dose- proportional increase in plasma Cmax and AUC § Accu

  13. Slide 13: Pharmacokinetic Results (Trough Levels After Multiple Dosing)

    Pharmacokinetic Results (Trough Levels After Multiple Dosing) Part B, Cohort 7N-9N § Fast achievement of steady-state after 4-7 days of dosing § Fast drop in plasma concentration following end of treatment according to terminal plasma Favorable pharmacokinetic half-life properties for IMU-856 § Mean

  14. Slide 14: Overall Summary of TEAE, SAE and AE Severity

    Overall Summary of TEAE, SAE and AE Severity Part B, Cohorts 7, 7N-9N Treatment Cohort 7* Cohort 7N Cohort 8N Cohort 9N Active Placebo Category 40 mg 40 mg 80 mg 160 mg (N=19) (N=7) (N=2) (N=5) (N=6) (N=6) Subjects with TEAEs, n (%) 2 (100%) 4 (80%) 5 (83%) 4 (67%) 15 (79%) 5 (71%) Once-daily 14-day

  15. Slide 15: Most Common Treatment-Emergent Adverse Events

    Most Common Treatment-Emergent Adverse Events Part B, Cohorts 7, 7N-9N Number (%) of subjects with TEAEs occurring in more than 2 subjects [Number of TEAEs reported] MedDRA Cohort 7* Cohort 7N Cohort 8N Cohort 9N Preferred Term 40 mg 40 mg 80 mg 160 mg Active Placebo Once-daily oral (N=19) (N=7) (N=

  16. Slide 16: Most Common IMP-related Treatment-Emergent Adverse Events

    Most Common IMP-related Treatment-Emergent Adverse Events Part B, Cohorts 7, 7N-9N Number (%) of subjects with IMP-related TEAEs occurring in 2 and more subjects [Number of TEAEs reported] MedDRA Cohort 7* Cohort 7N Cohort 8N Cohort 9N Active Placebo Preferred Term 40 mg 40 mg 80 mg 160 mg (N=19) (N

  17. Slide 17: Laboratory Parameters: No Change in Neutrophils Compared to Placebo

    Laboratory Parameters: No Change in Neutrophils Compared to Placebo Part B, Cohorts 7, 7N-9N Laboratory Values Over Time Individual Laboratory Values Hematology - Neutrophils Hematology - Neutrophils 17 | © Immunic, Inc. | Sep/20/2022

  18. Slide 18: Laboratory Parameters: No Hy's Law Range Cases Observed

    Laboratory Parameters: No Hy’s Law Range Cases Observed Part B, Cohorts 7, 7N-9N Bilirubin vs. ALT Showed Bilirubin vs. AST Showed No Evidence of DILI Potential No Evidence of DILI Potential 18 | © Immunic, Inc. | Sep/20/2022 ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; DILI: drug

  19. Slide 19: Multiple Doses of IMU-856 Found to Have a Favorable Safety and Tolerability Profile

    Multiple Doses of IMU-856 in Healthy Human Subjects Found to Have a Favorable Safety and Tolerability Profile Part B, Cohorts 7, 7N-9N No IMP-related serious adverse events No dose-dependency in adverse events No maximum tolerated dose reached No trends for post-dose changes in any laboratory parame

  20. Slide 20: Conclusions

    Conclusions Part B: 14-Day Multiple Ascending Doses § Daily oral doses of IMU-856 (up to 160 mg) demonstrated a favorable safety, tolerability and pharmacokinetic profile. § This allowed a smooth transition from Part B (MAD) to Part C (28-day dosing in patients with celiac disease) which is currentl

  21. Slide 21: Celiac Disease is a Serious Autoimmune Disease

    Celiac Disease is a Serious Autoimmune Disease Celiac disease is a multifactorial, complex autoimmune disease caused by an immune reaction against a degradation product of gluten and is strongly associated with specific HLA gluten protein gut lumen class II gene variants (HLA-DQ2 and -DQ8)[1] gliadi

  22. Slide 22: Celiac Disease Currently Has No Adequate Treatment Options

    Celiac Disease Currently Has No Adequate Treatment Options How much is 10 mg of gluten? The Only Option Today Symptomatic Patients is a Gluten Free Diet[1] Despite Gluten Free Diet Like a pin-point § The only established therapeutic § Between 24% and 47% of of flour option is a life-long strict pati

  23. Slide 23: Patients Across the Spectrum of Celiac Disease Need Access to a Drug Treatment

    Patients Across the Spectrum of Celiac Disease Need Access to a Drug Treatment to Address Persistent Disease Activity Despite GFD Patients with celiac disease are often wrongly diagnosed in early stages, leading to poorer prognosis on gluten free diet Active Celiac Disease § Numerous, intense Persis

  24. Slide 24: Phase 1 Clinical Trial of IMU-856: Part C in Celiac Disease Patients

    Phase 1 Clinical Trial of IMU-856 Part C in Celiac Disease Patients Flow Chart of Part C in Celiac Disease Proof-of-Concept Study § Part C includes a well-controlled celiac Day 1-28: Treatment IMU-856/placebo Day 14-28: disease patient population, designed to Gluten challenge with 6 g/daily assess s

  25. Slide 25: Q&A Session

    02 Phase 1 Clinical Trial of IMU-856 Q&A Session

  26. Slide 26: Summary and Outlook

    03 IMU-856: Restoring Intestinal Barrier Function Summary and Outlook

  27. Slide 27: IMU-856: Favorable Phase 1 Safety, Tolerability and Pharmacokinetic Profile

    IMU-856: Favorable Phase 1 Safety, Tolerability and Pharmacokinetic Profile § IMU-856 showed a favorable safety, tolerability and pharmacokinetic profile in this phase 1 clinical trial with no IMP- related serious adverse events seen in the SAD and MAD parts. § In particular, IMU-856 was safe and we

  28. Slide 28: Outlook: Multiple Value Inflection Points Expected Across Three Clinical-Stage Programs

    Outlook: Multiple Value Inflection Points Expected Across Immunic’s Three Clinical-Stage Programs Vidofludimus Calcium (IMU-838) § Interim data of phase 2 CALLIPER trial in PMS expected in H2/2023 and top-line data expected at the end of 2024 § Read-out of the first of the phase 3 ENSURE trials in R

  29. Slide 29: Thank You!

    Thank You! Immunic, Inc. 1200 Avenue of the Americas Immunic AG New York City, NY 10036 Gräfelfing (Munich) USA Germany Immunic Research GmbH Weinberg Campus Halle (Saale) Jessica Breu Germany Head of IR & Communications Phone: +49-89-2080477-09 Email: ir@imux.com Immunic Australia Pty. Ltd. Web: ww

Immunic — Technical Presentation (September 2022) on 6ix